BioSpace News Archive

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its American Depositary Shares (“ADSs”),

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the closing of its previously announced underwritten public offering of 5,972,222 shares of its common stock

Treace Medical Concepts, Inc., a privately-held medical device company focused on advancing the standard of care for hallux valgus (bunion) surgery, announced today that its Board of Directors has appointed John K. Bakewell and Lawrence W. Hamilton as members of the Board.

Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization, Eli Lilly and Company (NYSE: LLY) announced

AbCellera today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), was granted authorization by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2020

Correlia Biosystems, a Berkeley, CA based life science startup, announced today that it has closed a $7 million Series A financing round with select global investors. Neotribe Ventures led the investment round, joined by Cota Capital, the Regents of the University of California, and others.

Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses: the FDA-approved dose of 24 mg once daily versus a lower dose of 18 mg once daily in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).

AMCP Foundation recognizes Montrell Taylor, 2021 PharmD Candidate at Howard University College of Pharmacy, for his successful completion of the Genentech Evidence for Access Summer Internship Program.

AMCP Foundation recognizes two student pharmacists from the University of Southern California and University of Washington for the successful completion of the Specialized Summer Internship Program in Health Outcomes, sponsored by AbbVie, Inc.